Spots Global Cancer Trial Database for Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Official Title: Open-label Rollover Study to Evaluate Long-Term Safety in Subjects With Metastatic Solid Tumors That Are Benefiting From Continuation of Therapy With Sacituzumab Govitecan
Study ID: NCT04319198
Conditions
Interventions
Study Description
Brief Summary: The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, and how safe it is in participants with metastatic cancer (cancer that has spread).
Detailed Description: This is a rollover study. Only participants who continue to receive clinical benefit from continuation of sacituzumab govitecan-hziy therapy and are tolerating therapy at the time of enrollment are eligible for this study. Participants enrolled may continue to receive sacituzumab govitecan-hziy at the dose that they were receiving in the Gilead parent study at the time of consenting to participate in this rollover study.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California San Francisco, San Francisco, California, United States
Rocky Mountain Cancer Center, Aurora, Colorado, United States
Christiana Care Health Services, Christiana Hospital, Newark, Delaware, United States
Florida Cancer Specialists & Research Institute, Fort Myers, Florida, United States
Baptist Health - Miami Cancer Institute, Miami, Florida, United States
Illinois Cancer Specialists, Arlington Heights, Illinois, United States
University of Chicago, Chicago, Illinois, United States
University of MD Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
New York Cancer & Blood Specialists - Setauket Medical Oncology, Port Jefferson, New York, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Next Oncology, Austin, Texas, United States
Oncology Consultants,P.A., Houston, Texas, United States
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
NEXT Oncology, San Antonio, Texas, United States
Institut Jules Bordet, Bruxelles, , Belgium
CHU UCL NAMUR - Sainte Elisabeth, Namur, , Belgium
Institut Bergonie, Bordeaux Cedex, , France
Centre Leon Berard, Lyon, , France
Institut Claudius Regaud, Toulouse Cedex 9, , France
Contact Details
Name: Gilead Study Director
Affiliation: Gilead Sciences
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
